Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
AstraZeneca
Boehringer Ingelheim
Express Scripts
Baxter

Last Updated: November 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Empagliflozin; Metformin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01001962 Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics Not yet recruiting Aristotle University Of Thessaloniki Phase 4 2016-01-01 Objectives: Primary 1. Primary prevention of new onset of hypertension Secondary 1. Reduction of 24h BP in type II diabetics with prehypertension 2. Reduction of non dipping status, day and nighttime BP, morning BP surge in subjects receiving EMPAGLIFLOZIN 3. Reduction in the total cardiovascular risk 4. 3 years morbidity and mortality rates 5. Arterial de-stiffening, reduction in central aortic blood pressure in subjects receiving EMPAGLIFLOZIN
NCT01159600 Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 2010-07-01 The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.
NCT01159600 Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 2010-07-01 The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Empagliflozin; Metformin Hydrochloride

Condition Name

Condition Name for Empagliflozin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 14
Healthy 13
Type 2 Diabetes Mellitus 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Empagliflozin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus 27
Diabetes Mellitus, Type 2 26
Hypertension 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Empagliflozin; Metformin Hydrochloride

Trials by Country

Trials by Country for Empagliflozin; Metformin Hydrochloride
Location Trials
United States 184
Canada 44
Germany 18
Australia 12
Mexico 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Empagliflozin; Metformin Hydrochloride
Location Trials
Texas 13
Florida 11
Georgia 10
California 9
North Carolina 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Empagliflozin; Metformin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Empagliflozin; Metformin Hydrochloride
Clinical Trial Phase Trials
Phase 4 10
Phase 3 13
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Empagliflozin; Metformin Hydrochloride
Clinical Trial Phase Trials
Completed 20
Not yet recruiting 11
Recruiting 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Empagliflozin; Metformin Hydrochloride

Sponsor Name

Sponsor Name for Empagliflozin; Metformin Hydrochloride
Sponsor Trials
Boehringer Ingelheim 25
Eli Lilly and Company 17
Sanofi 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Empagliflozin; Metformin Hydrochloride
Sponsor Trials
Industry 51
Other 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Harvard Business School
AstraZeneca
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.